Spinocerebellar Ataxia Type 2 (ATXN2) Gene Mutation Analysis
Spinocerebellar ataxias (SCAs) are a clinically and genetically heterogeneous group of autosomal dominant neurodegenerative disorders characterized by progressive cerebellar dysfunction. Common clinical manifestations include gait and limb ataxia, dysarthria, slow saccadic eye movements, hyperreflexia, and dysphagia. In some cases, patients may also present with ophthalmoparesis, tremor, or parkinsonism. Spinocerebellar ataxia type 2 (SCA2) is among the most common SCAs, typically presenting in the third to fourth decade of life with a disease duration of 10–15 years.
Because the disorder follows an autosomal dominant inheritance pattern, each offspring of an affected individual has a 50% risk of inheriting the pathogenic allele. SCA2 results from CAG trinucleotide repeat expansion in the ATXN2 gene located on chromosome 12q24.12, which encodes the ataxin-2 protein. Normal ATXN2 alleles contain fewer than 31 CAG repeats. Expansion beyond the normal range leads to the production of abnormally long polyglutamine (polyQ) tracts in the ataxin-2 protein. These elongated proteins are neurotoxic, disrupting RNA metabolism, protein homeostasis, mitochondrial function, and calcium signaling, ultimately causing selective neuronal loss within the cerebellum, brainstem, and spinal cord. Interestingly, ATXN2 intermediate-length expansions (30–32 CAG repeats) have been identified as risk alleles for amyotrophic lateral sclerosis (ALS), further highlighting the gene’s pathogenic significance across neurodegenerative disorders.
- Confirms molecular diagnosis of spinocerebellar ataxia type 2 (SCA2)
- Supports carrier detection and genetic counseling and prognostic evaluation testing in at-risk individuals and family members.
- Contributes to differential diagnosis of hereditary ataxias and neurodegenerative disorders such as ALS
≤30 repeats Normal (non-pathogenic)
Whole blood (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: unacceptable
- Adv Exp Med Biol. 2018;1049:175-195. [PMID: 29427103]
- Ann Neurol. 2016 Oct;80(4):600-15. [PMID: 27531668]
- Neural Regen Res. 2022 Nov;17(11):2445-2447. [PMID: 35535893]
- Curr Opin Neurol. 2021 Aug 1;34(4):578-588. [PMID: 34010218]
- Neurol Sci. 2025 Oct;46(10):5417-5421. [PMID: 40581671]